ProLynx collaborates with Daiichi Sankyo on drug delivery

The collaboration will evaluate the utility of the releasable linker technology in half-life extension of small-molecule drugs after intravitreal injection

The drawing depicts microspheres formed from highly -homogeneous Tetra-PEG hydrogels that serve as sub-cutaneous depots for a novel drug-delivery system. Picture courtesy of ProLynx

ProLynx is to collaborate with international pharmaceutical company Daiichi Sankyo Co to evaluate its drug delivery linker technology in the eye.

In the ProLynx half-life extension platform technology, a drug is tethered to a carrier by a self-cleaving beta-eliminative linker that is pre-programmed to release the drug at a pre-determined rate.

After injection, the drug is slowly released from the carrier depot.

The ProLynx-Daiichi Sankyo collaboration will evaluate the utility of the releasable linker technology in half-life extension of small-molecule drugs after intravitreal injection.

Daniel Santi, co-founder and President of ProLynx, said: “There are numerous opportunities for our half-life extension technology in localised delivery of drugs. Small, local compartments – such as the eye – should retain therapeutic concentrations of the released free drug for prolonged periods before the drug is distributed systemically.”

Based in San Francisco, CA, ProLynx is a privately held biotechnology company developing proprietary drug delivery systems for half-life extension of proteins, peptides and small molecules. The company is seeking to apply its technology to extend half-lives of drug candidates of pharmaceutical companies, and to improve properties of off-patent therapeutics.

Companies